Mothers' acceptance of human papillomavirus (HPV) vaccination for daughters in a country with a high prevalence of HPV.
Cervical cancer is the second most common cancer among women in Argentina and the mortality rate is not declining despite opportunistic screening. Free-of-charge human papillomavirus (HPV) vaccination of 11-year-old girls was introduced in 2011. Parental acceptance of HPV vaccination is considered to be of great importance for HPV vaccine uptake. However, little is known regarding this factor in Argentina. The aim of the present study was to explore maternal HPV vaccination acceptance, willingness to pay for HPV vaccination and correlates of this willingness, awareness of HPV and HPV-associated disease and behaviors and attitudes associated with HPV vaccination acceptance. A total of 180 mothers of girls aged 9-15 years comprised this quantitative, cross-sectional, survey-based study, conducted at two hospitals in the Mendoza Province. Correlates of willingness to pay for HPV vaccination were obtained using multivariable logistic regression models. Maternal HPV vaccination acceptance was 90%, and 60% of mothers were willing to pay for HPV vaccination. Mothers who were gainfully employed and had a higher disposable household income were significantly more willing to pay for HPV vaccination [odds ratio (OR)=2.54, 95% confidence interval (CI) 1.01-6.38; OR=3.28, 95% CI 1.36-7.94, respectively], as were mothers who were aware of cervical cancer prior to the study (OR=3.22, 95% CI 1.02-10.14). Only one in 10 mothers were informed that HPV vaccination does not offer complete protection against cervical cancer. In conclusion, the present study showed high maternal HPV vaccination acceptance, although acceptance decreased when vaccination was not free-of-charge. Continuous public education campaigns are needed to improve knowledge of HPV, HPV vaccines and HPV-associated disease.
Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden.
Susanna
S
Alder
Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden.
Sofia
S
Gustafsson
Department of Obstetrics and Gynecology, Docent Extension National University of Cuyo, Regional Hospital Diego Paroissien, Godoy Cruz 475, Maipú, Mendoza, Argentina.
Claudia
C
Perinetti
Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden.
Miriam
M
Mints
Department of Laboratory Medicine, Karolinska Institutet and Hospital, 141 83 Stockholm, Sweden.
Karin
K
Sundström
Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden.
Sonia
S
Andersson
D000293:Adolescent; D000328:Adult; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007114:Immunization / Q000379:methods; D008875:Middle Aged; D009679:Nuclear Family; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D015995:Prevalence; D011795:Surveys and Questionnaires; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D014611:Vaccination / Q000379:methods; D055815:Young Adult
D053918:Papillomavirus Vaccines